These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8048801)

  • 1. Tumor markers: FDA review and evaluation.
    Aziz KJ
    Ann Clin Lab Sci; 1994; 24(3):282-3. PubMed ID: 8048801
    [No Abstract]   [Full Text] [Related]  

  • 2. AACR-FDA-NCI cancer biomarkers collaborative.
    Yu LR; Veenstra TD
    Expert Rev Mol Diagn; 2007 Sep; 7(5):507-9. PubMed ID: 17892359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical devices; reclassification of tumor-associated antigen immunological test system--FDA. Final rule.
    Fed Regist; 1997 Dec; 62(242):66003-5. PubMed ID: 10179301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New health initiatives to improve cancer treatments.
    FDA Consum; 2006; 40(3):36-7. PubMed ID: 16906666
    [No Abstract]   [Full Text] [Related]  

  • 5. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
    Aziz KJ; Sliva CA; Gutman SI
    Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
    [No Abstract]   [Full Text] [Related]  

  • 7. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assignment of agency component for review of premarket applications--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58754-8. PubMed ID: 10115697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.
    Karsdal MA; Henriksen K; Leeming DJ; Mitchell P; Duffin K; Barascuk N; Klickstein L; Aggarwal P; Nemirovskiy O; Byrjalsen I; Qvist P; Bay-Jensen AC; Dam EB; Madsen SH; Christiansen C
    Biomarkers; 2009 May; 14(3):181-202. PubMed ID: 19399662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and medicine. Recruiting genes, proteins for a revolution in diagnostics.
    Service RF
    Science; 2003 Apr; 300(5617):236-9. PubMed ID: 12690164
    [No Abstract]   [Full Text] [Related]  

  • 11. Medical devices; clinical chemistry and clinical toxicology devices; instrumentation for clinical multiplex test systems. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Mar; 70(46):11867-9. PubMed ID: 15762011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update of FDA's Critical Path Initiative.
    Khleif S
    Clin Adv Hematol Oncol; 2009 Mar; 7(3):173-4. PubMed ID: 19398939
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical devices; exemptions from premarket notification; class II devices--FDA, Final rule.
    Fed Regist; 1998 Nov; 63(212):59222-31. PubMed ID: 10187384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary markers in the detection of bladder cancer: what's new?
    Nielsen ME; Schaeffer EM; Veltri RW; Schoenberg MP; Getzenberg RH
    Curr Opin Urol; 2006 Sep; 16(5):350-5. PubMed ID: 16905981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction to the Food and Drug Administration (FDA) regulatory process.
    Hackett JL; Gutman SI
    J Proteome Res; 2005; 4(4):1110-3. PubMed ID: 16083260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration.
    Phillips KA; Van Bebber SL
    Med Care Res Rev; 2006 Jun; 63(3):301-26. PubMed ID: 16651395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delegations of authority and organization; Office of the Commissioner--FDA. Final rule.
    Fed Regist; 1991 Nov; 56(225):58758. PubMed ID: 10115698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson.
    Woodcock J
    Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical chemistry and clinical toxicology devices advisory panel recommendation on Glucowatch.
    Klonoff DC
    Diabetes Technol Ther; 2000; 2(1):125-6. PubMed ID: 11467313
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.